Skip to main content
. 2010 Sep 21;7(1):4–11. doi: 10.1007/s13181-010-0115-5

Table 3.

Cases with and without PCC consultation

PCC consult No PCC consult Difference in mean or prevalence
N (%) 295 (67.8) 140 (32.2) 35.6
Mean age (95% CI) 29.2 (27.4, 31.1) 28.8 (26.2, 31.5) 0.4 (−2.9, 3.7)
Females (%) 215 (72.9) 104 (74.3) 1.4
Mean LOS in hours (95% CI) 61.9 (57.2, 66.5) 76.3 (66.6, 86.0) 14.4 (5.0, 23.9)
Mean ED LOS in hours (95% CI) 6.1 (5.5, 6.7) 5.3 (4.8, 5.9) 0.8 (−0.2, 1.7)
Mean lab clearance to discharge in hours (95% CI) 33.1 (29.3, 36.9) 39.4 (31.9, 47.0) 6.3 (−1.2, 13.9)
Mean TOI to presentation in hours (95% CI) 10.0 (8.2, 11.9) 8.9 (6.9, 10.8) 1.2 (−2.4, 4.7)
Ingestion type
 Accidental (%) 46 (15.7) 22 (15.7) 0
 Intentional (%) 245 (83.3) 114 (81.4) 1.9
 Unknown (%) 3 (1.0) 4 (2.9) 1.9
Co-ingestants (%) 155 (52.7) 65 (46.4) 6.3
Mean TOI to NAC (95% CI) 12.6 (10.4, 14.9) 11.5 (9.2, 13.9) 1.1 (−2.6, 4.8)
IV NAC (%) 74 (25.1) 29 (21.2) 3.9
SDAC in ED (%) 139 (32.0) 70 (16.1) 15.9
Patients with liver enzyme elevation (%) 94 (31.9) 51 (36.4) 4.5
Significant liver enzyme elevation (%)a 39 (13.2) 24 (17.1) 3.9
Patients with highest recorded INR > 1.3 (%)b 45 (17.0) 32 (25.6) 8.6
Transfer for OLT/Received OLT (%) 3/0 (1.0) 5/0 (3.6) 2.6
Deaths (%) 1 (0.3) 3 (2.1) 1.8
Nomogram placementc
 Above “200” line (%) 105 (53.3) 56 (60.9) 7.6
 Between “150” and “200” lines (%) 32 (16.2) 19 (20.7) 4.5
 Below “150” line (%) 60 (30.5) 17 (18.5) 12.0
Mean highest APAP level (95% CI) 101.0 (91.7, 110.4) 119.0 (105.0, 133.0) 18.0 (1.38, 34.5)

LOS length of stay, TOI time of ingestion, PCC poison control center, NAC N-acetylcysteine, AC activated charcoal, OLT orthotopic liver transplantation

aSignificant liver enzyme elevation is defined as AST and/or ALT >1,000 IU/L

bOf cases with recorded INR

cOf cases appropriate for Rumack–Matthews nomogram placement